San Diego, Calif., April 5, 2016 – Forge Therapeutics, Inc., a biotechnology company discovering innovative therapeutics using a breakthrough drug discovery platform targeting metalloproteins, announced today that Zachary A. Zimmerman, Ph.D., CEO of Forge, will present a corporate overview at the Needham Healthcare Conference being held at the Westin NY Grand Central Hotel, New York, NY on April 12th & 13th, 2016. The presentation will be webcast and can be accessed on the events page of Forge’s website at


Details of Forge’s presentation:


Event:            Needham & Company’s 15th Annual Healthcare Conference

Date:              Wednesday, April 13th

Time:             9:00 AM EST

Location:       Westin NY Grand Central Hotel, New York, NY



About Forge Therapeutics, Inc.

Forge Therapeutics, Inc. (“Forge”) is a biotechnology start-up that leverages its novel chemistry platform to develop small molecule inhibitors to target metalloproteins. Metalloproteins are proteins that require metal ions for their biological function and make up over 1/3 of the proteins in the human body. Forge uses a proprietary approach comprised of molecular modeling for rational drug design along with fundamental knowledge and expertise in bioinorganic chemistry to target metalloproteins.  The name Forge Therapeutics comes from two definitions for forge: to manipulate (inhibit) a metal object (metalloprotein) and to move forward steadily with a purpose (the Forge team). Forge Therapeutics, Inc., maintains its headquarters in San Diego, California. To learn more please visit


About Needham Healthcare Conference

Needham & Company’s 15th Annual Healthcare Conference is a high-impact forum for institutional investors and venture capital firms to hear the latest updates from senior management teams of both leading public and private companies in the Biotechnology, Specialty Pharmaceuticals, Medical Technology and Diagnostics sectors.